What it is
IGF-1 DES is a research peptide variant designed to target musculoskeletal tissues. It is formulated as a single-ingredient option for targeted application.
1 mg · vegan · gluten-free · 30 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
IGF-1 DES is a research peptide variant designed to target musculoskeletal tissues. It is formulated as a single-ingredient option for targeted application.
This peptide is researched for its potential to interact with IGF-1 receptors in muscles and joints, influencing cellular processes related to tissue repair and function. Effects on joint comfort may become apparent within 4-12 weeks.
Adults looking to address joint stiffness, muscle weakness, joint pain. Particularly relevant for people who prefer a targeted single ingredient and who have ruled out an underlying condition that needs medical care first.
Pregnant or nursing women without clinician oversight. People on prescription medication affecting the same pathway should consult a doctor before combining. Side effects are uncommon at recommended doses but mild GI upset can occur when starting.
C · C · emerging-to-moderate human evidence for joint and musculoskeletal health
SacredBod's longer take on IGF-1 DES — context the structured blocks above don't capture.
IGF-1 DES is a peptide supplement used to support joint and musculoskeletal health. IGF-1 variant researched for muscle (research-only). It is available in capsule form and dosed for adults in India and internationally. As a peptide-tradition entry in the SacredBod catalog, it is positioned as a single-ingredient option that can be used on its own or layered into a broader protocol. IGF-1 DES works through the mechanisms characteristic of its class — see the mechanism and research sections for detail. It primarily acts on the joints, muscles, bones, and effects are dose-dependent, typically becoming measurable within 4-12 weeks for joint comfort. Consistency matters more than dose size for this category.
IGF-1 DES carries an evidence grade of C in the SacredBod catalog, reflecting emerging human evidence for joint and musculoskeletal health. IGF-1 variant researched for muscle (research-only). Benefits are cumulative rather than immediate, typically becoming noticeable within 4-12 weeks for joint comfort, and individual response varies.
A typical dose is 1 mg, taken with food, usually in the morning. Start at the lower end, assess tolerance, and stay consistent; more is not automatically better.
Pregnant or nursing women without clinician oversight. People on prescription medication affecting the same pathway should consult a doctor before combining. Side effects are uncommon at recommended doses but mild GI upset can occur when starting.
Adults looking to address joint stiffness, muscle weakness, joint pain. Particularly relevant for people who prefer a targeted single ingredient and who have ruled out an underlying condition that needs medical care first.
As part of the Peptide category, IGF-1 DES can be used on its own or layered into a broader protocol — see the Goes with panel for evidence-aligned pairings.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
Request received.
We'll route this to a clinician familiar with peptide protocols. Expect a reply within about 48 hours.
How's your experience? We read every note.